Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 22, 2017

CTD Holdings starts enrolment in Phase I/II trial of Trappsol Cyclo for NPC

US-based biotechnology firm CTD Holdings has started patient enrolment in the Phase I/II clinical trial of Trappsol Cyclo to treat patients suffering from Niemann-Pick disease type C (NPC) in Europe.

US-based biotechnology firm CTD Holdings has started patient enrolment in the Phase I/II clinical trial of Trappsol Cyclo to treat patients suffering from Niemann-Pick disease type C (NPC) in Europe.

Trappsol Cyclo is a parenteral grade of a molecule known as hydroxypropyl beta-cyclodextrin, which comprises seven glucopyranose units.

The Phase I/II trial is designed to assess the safety and efficacy of intravenous Trappsol Cyclo in 12 NPC patients aged two and above.

Trappsol Cyclo will be evaluated at 1,500mg/kg, 2,000mg/kg and 2,500mg/kg doses administered bi-weekly for 48 weeks.

While the first patient was recruited at Salford NHS Trust in the UK, additional clinical centres in the UK, Sweden and Italy will be included in the trial.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

CTD chairman and CEO Scott Fine said: "Enrolment of the first patient at the Salford clinical site is a significant milestone for the company in the development of this treatment for a devastating disease.

"Enrolment of the first patient at the Salford clinical site is a significant milestone for the company in the development of this treatment for a devastating disease."

“In addition, we anticipate enrolling the first patient in our US Phase I clinical trial of Trappsol Cyclo in the near future.”

Expected to report final results by the end of next year, the trial’s primary objective is determination of the injection's optimum dose for further study.

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) previously granted fast-track designation and orphan drug designation for Trappsol Cyclo in NPC.

The data from administration of the injection to a total of 21 patients showed improvements in neurological symptoms, lung function or liver morphology, stabilisation of disease progression and no significant safety concerns.


Image: Niemann-Pick disease. Photo: courtesy of humpath.com.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU